# US 11,994,510 B2 · Diagnosis and treatment of Fusariosis and Scedosporiosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,994,510 B2
- Document ID: US11994510B2
- Status: Granted
- Kind: B2
- Application number: 16/341,265
- Filed: 2017-10-11
- Published: 2020-02-06
- Granted: 2024-05-28
- Earliest claimed: 2016-10-11
- Assignees: The Brigham and Women's Hospital, Inc.
- Applicants: The Brigham and Women's Hospital, Inc.
- Inventors: Sophia Koo
- Web page: https://patentgrep.com/patent/US11994510B2

## CPC

- G01N 33/497: of gaseous biological material, e.g. breath
- A61P 31/10: Antimycotics
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- G01N 33/4977: {Metabolic gas from microbes, cell cultures or plant tissues}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods for diagnosing, treating, and monitoring the treatment of fusariosis or scedosporiosis are described. The methods can include detecting the presence of one or more volatile organic compounds (VOCs) in the breath of subjects suspected of having fusariosis or scedosporiosis.

## Claims

### Claim 1

A method for diagnosing and treating a subject with scedosporiosis, the method comprising:
obtaining a sample comprising breath of a subject suspected of comprising Scedosporium species fungi isolated from the subject;
detecting the presence of two, three, or more volatile organic compounds (VOCs) produced by the Scedosporium species in the sample comprising breath from the subject suspected of comprising Scedosporium isolated from the subject, wherein the VOCs are selected from the group consisting of (a) 1H-Indene, 2,3,3a,4-tetrahydro-3,3a,6-trimethyl-1-(1-methylethyl)-, (b) β-guaiene, (c) β-longipinene, (d) β-gurjunene, and (e) isocomene;
diagnosing the subject as having scedosporiosis when there are two, three or more of the VOCs present in the sample; and
administering an antifungal treatment to the subject diagnosed as having scedosporiosis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment comprises administration of one or more doses of one or more antifungal compounds.

### Claim 3

A method of treating a subject who is diagnosed as having an Scedosporium apiospermum, S. prolificans, or S. boydii infection, the method comprising:
obtaining a sample comprising breath of a subject suspected of comprising Scedosporium apiospermum, S. prolificans, or S. boydii isolated from the subject; and:
diagnosing the subject as having an S. apiospermum infection based on the presence of (a) 1H-Indene, 2,3,3a,4-tetrahydro-3,3a,6-trimethyl-1-(1-methylethyl)-, (b) β-guaiene, (c) (β-longipinene, (d) (β-gurjunene, and (e) isocomene in the sample ;
diagnosing the subject as having an S. prolificans infection based on the presence of only himachalene and γ-gurjunene in the sample ; and
diagnosing the subject as having an S. boydii infection based on the presence of only γ-gurjunene in the sample;
and administering an antifungal treatment to the subject who is diagnosed as having the Scedosporium apiospermum, S. prolificans, or S. boydii infection.

### Claim 4 (depends on 1)

The method of claim 1, further comprising:
determining a first level of the two, three, or more VOCs produced by the Scedosporium species in the sample from the subject before administration of the antifungal treatment;
determining a second level of the VOCs in a sample obtained after administration of the antifungal treatment to the subject; and
comparing the first and second levels of VOCs, wherein a decrease in the VOCs indicates that the treatment has been effective in treating the scedosporiosis in the subject, and an increase or no change indicates that the treatment has not been effective in treating the scedosporiosis in the subject.

### Claim 5 (depends on 1)

The method of claim 1, wherein determining the presence of a VOC comprises assaying the sample to detect the presence of the VOC.

### Claim 6 (depends on 5)

The method of claim 5, wherein assaying the sample to detect the presence of the VOC comprises using a gas chromatography (GC) or spectrometry method.

### Claim 7 (depends on 6)

The method of claim 6, wherein the spectrometry method is mobility spectrometry (IMS) or differential mobility spectrometry (DMS).

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 9 (depends on 5)

The method of claim 5, wherein the subject is a human.

### Claim 10 (depends on 2)

The method of claim 2, wherein the antifungal compound is an amphotericin B formulation or an azole antifungal compound.